NCT03681548 - A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

February 8, 2019

Study Completion Date

March 7, 2019

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG

Doxorubicin Hydrochloride Liposome Injection

50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation

Trial Locations (15)

390021

Aman Hospital and Research Center, Vadodara

391760

Kailash Cancer Hospital And Research Center, Vadodara

395002

Nirmal Hospital Pvt. Ltd., Surat

Unique Hospital - Multispeciality and Research Institute, Surat

411013

Noble Hospital Pvt Ltd., Pune

422002

HCG Manavata Cancer Centre, Nashik

500004

MNJ Institute of Oncology & Regional Cancer Center, Hyderabad

520002

HCG City Cancer Centre, Vijayawada

530017

Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam

570001

K R Hospital, Mysore

600116

Sri Ramachandra Medical Centre, Chennai

602105

Saveetha Medical College & Hospital, Chennai

641005

VGM Hospital, Coimbatore

751007

Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneshwar

422 002

Apex Wellness Rishikesh Hospital, Nashik